hotspot -WSS

hotspot

author：explore 2025-10-01 17:19:57 - browse：6819

Duchenne muscular dystrophy is a devastating disease and, until very recently, was one without much hope. When Hawken Miller was diagnosed at age 5, the physician told his parents to enjoy the time they had with him, as there wouldn’t be much. Over 20 years later, Miller is a journalist and content strategist for CureDuchenne, an organization started by his mother when he was diagnosed, and new treatment is on the horizon.

Last month, the FDA approved a new gene therapy from Sarepta Therapeutics that will provide hope for many patients and families. The new drug, however, has its limitations — it’s only approved for children age 4-5, for example. Miller joined the podcast to discuss how this drug may change lives, what more needs to happen, and what his personal experience has been living with Duchenne.

“For the older boys, we’re running up against the clock a little bit with what we’re able to do and what we’re not able to do,” Miller said. “And if we’re able to try anything that could possibly help, I think most people would like the opportunity to do that.”

The conversation is based off his recent First Opinion, “The FDA’s approval of a new gene therapy for Duchenne muscular dystrophy won’t help me — but it gives me hope.”

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： After sickle

hotspot

Wikipedia

entertainment

WSS

Tornado touches down near Chicago's O'Hare airport amid extreme weather nationwide

Sickle cell gene therapy cures need to be accessible in Africa

STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc

Patients' immediate access to test results puts radiologists in a bind

SCOTUS to consider access to abortion pill mifepristone

Pharma patents targeted by Biden in move to slash drug prices

focus

hotspot

leisure time

Affirmative action in medical school literally saved lives

STAT letters to the editor on burnt

FDA approval of Sarepta Duchenne genetic therapy gives me hope

What causes an itch? Researchers may have solved the mystery

Jerome Adams on the need for new antivirals for Covid

Patients' immediate access to test results puts radiologists in a bind

Heart attack and stroke risk calculators need revising

What PEPFAR has meant on the ground in Ukraine

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Superbugs, antibiotic resistance get scrutiny in congress

explore

EU fines Illumina $475 million over Grail acquisition

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

Blinken talks high

Grail's uphill battle for Medicare to cover its cancer screening test

Pharma patents targeted by Biden in move to slash drug prices

Russia's threat to pull out of Ukraine grain deal raises fears about global food security

hotspot

Wikipedia

entertainment

focus